Document is current
Any future updates will be listed below
-
Authors
Fessenden, Tim B
Stopfer, Lauren E
Chatterjee, Fiona
Zulueta, Julian
Mesfin, Josh
Cordero Dumit, Therese https://orcid.org/0000-0003-2406-0350
Reijers, Irene
Hoefsmit, Esmee P https://orcid.org/0000-0002-3989-8175
Blank, Christian
White, Forest
Spranger, Stefani https://orcid.org/0000-0003-3257-4546
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct02977052 at ClinicalTrials.govnct02977052 at ClinicalTrials.govDocuments that mention this clinical trial
The impact of response-directed surgery and adjuvant therapy on long-term survival after neoadjuvant ipilimumab plus nivolumab in stage III melanoma: Three-year data of PRADO and OpACIN-neo.
https://doi.org/10.1200/jco.2023.41.16_suppl.101
Dendritic cell-mediated cross presentation of tumor-derived peptides is biased against plasma membrane proteins
https://doi.org/10.1136/jitc-2021-004159
L3 Update of the OpACIN and OpACIN-neo trials: 36-months and 24-months relapse-free survival after (neo)adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma patients
https://doi.org/10.1136/jitc-2020-itoc7.3
34th Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2019): part 1
https://doi.org/10.1186/s40425-019-0763-1
The impact of emotional distress on pathologic response and survival after neoadjuvant combination immune checkpoint blockade (ICB) in high-risk stage III melanoma.
https://doi.org/10.1200/jco.2023.41.16_suppl.9558
Neoadjuvant immunotherapy for non-small cell lung cancer: right drugs, right patient, right time?
https://doi.org/10.1136/jitc-2020-002248
Documents that mention this clinical trial
The impact of response-directed surgery and adjuvant therapy on long-term survival after neoadjuvant ipilimumab plus nivolumab in stage III melanoma: Three-year data of PRADO and OpACIN-neo.
https://doi.org/10.1200/jco.2023.41.16_suppl.101
Dendritic cell-mediated cross presentation of tumor-derived peptides is biased against plasma membrane proteins
https://doi.org/10.1136/jitc-2021-004159
L3 Update of the OpACIN and OpACIN-neo trials: 36-months and 24-months relapse-free survival after (neo)adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma patients
https://doi.org/10.1136/jitc-2020-itoc7.3
34th Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2019): part 1
https://doi.org/10.1186/s40425-019-0763-1
The impact of emotional distress on pathologic response and survival after neoadjuvant combination immune checkpoint blockade (ICB) in high-risk stage III melanoma.
https://doi.org/10.1200/jco.2023.41.16_suppl.9558
Neoadjuvant immunotherapy for non-small cell lung cancer: right drugs, right patient, right time?
https://doi.org/10.1136/jitc-2020-002248
-
Funding
Funding for this research was provided by:
Melanoma Research Alliance (Alliance Young Investigator Award (DOI: http://doi)
Melanoma Research Alliance (Team Science Award 565436 (DOI: https://doi.org/10)
- License Information
